



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/660,468	09/12/2000	Allan S. Lau	4099-0002.31	6858

22918 7590 12/17/2001

PERKINS COIE LLP  
P.O. BOX 2168  
MENLO PARK, CA 94026

EXAMINER

ROMEO, DAVID S

ART UNIT	PAPER NUMBER
----------	--------------

1647

DATE MAILED: 12/17/2001

5

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/660,468

Applicant(s)

LAU ET AL.

Examiner

David S Romeo

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 12 September 2000.
- 2a) ☐ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-24 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)                      4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)                      5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_                      6) ☐ Other: \_\_\_\_\_

Art Unit: 1647

## DETAILED ACTION

### *Election/Restriction*

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
5 IL-1- $\alpha$  and IL-1- $\beta$ , classified in class 530, subclass 350.
  - II. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and IL-2, classified in class 530, subclass 350.
  - III. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and IL-3, classified in class 530, subclass 350.
  - 10 IV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and IL-4, classified in class 530, subclass 350.
  - V. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and IL-5, classified in class 530, subclass 350.
  - VI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
15 IL-1- $\alpha$  and IL-6, classified in class 530, subclass 350.
  - VII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and IL-7, classified in class 530, subclass 350.

Art Unit: 1647

- VIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and IL-8, classified in class 530, subclass 350.
- IX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and IL-10, classified in class 530, subclass 350.
- 5 X. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and IL-11, classified in class 530, subclass 350.
- XI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and IL-12, classified in class 530, subclass 350.
- XII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
10 IL-1- $\alpha$  and IFN- $\alpha$ , classified in class 530, subclass 350.
- XIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and IFN- $\beta$ , classified in class 530, subclass 350.
- XIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and IFN- $\gamma$ , classified in class 530, subclass 350.
- 15 XV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and oncostatin, classified in class 530, subclass 350.
- XVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\alpha$  and TNF- $\alpha$ , classified in class 530, subclass 350.



Art Unit: 1647

XVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and TNF- $\beta$ , classified in class 530, subclass 350.

XVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and GM-CSF, classified in class 530, subclass 350.

5 XIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and G-CSF, classified in class 530, subclass 350.

XX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and M-CSF, classified in class 530, subclass 350.

10 XXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and sTNFR, classified in class 530, subclass 350.

XXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\alpha$  and IL-1ra, classified in class 530, subclass 350.

XXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\beta$  and IL-2, classified in class 530, subclass 350.

15 XXIV. Claim(s) 1-10, to the extent that they are drawn to a composition  
comprising IL-1- $\beta$  and IL-3, classified in class 530, subclass 350.

XXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising  
IL-1- $\beta$  and IL-4, classified in class 530, subclass 350.

Art Unit: 1647

- XXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-5, classified in class 530, subclass 350.
- XXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-6, classified in class 530, subclass 350.
- 5 XXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-7, classified in class 530, subclass 350.
- XXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-8, classified in class 530, subclass 350.
- 10 XXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-10, classified in class 530, subclass 350.
- XXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-11, classified in class 530, subclass 350.
- XXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-12, classified in class 530, subclass 350.
- 15 XXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IFN- $\alpha$ , classified in class 530, subclass 350.
- XXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IFN- $\beta$ , classified in class 530, subclass 350.

Art Unit: 1647

- XXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IFN- $\gamma$ , classified in class 530, subclass 350.
- XXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and oncostatin, classified in class 530, subclass 350.
- 5 XXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and TNF- $\alpha$ , classified in class 530, subclass 350.
- XXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and TNF- $\beta$ , classified in class 530, subclass 350.
- XXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition  
10 comprising IL-1- $\beta$  and GM-CSF, classified in class 530, subclass 350.
- XL. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and G-CSF, classified in class 530, subclass 350.
- XLI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and M-CSF, classified in class 530, subclass 350.
- 15 XLII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and sTNFR, classified in class 530, subclass 350.
- XLIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-1- $\beta$  and IL-1ra, classified in class 530, subclass 350.

Art Unit: 1647

XLIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-3, classified in class 530, subclass 350.

XLV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-4, classified in class 530, subclass 350.

5 XLVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-5, classified in class 530, subclass 350.

XLVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-6, classified in class 530, subclass 350.

10 XLVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-7, classified in class 530, subclass 350.

XLIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-8, classified in class 530, subclass 350.

L. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-10, classified in class 530, subclass 350.

15 LI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-11, classified in class 530, subclass 350.

LII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-12, classified in class 530, subclass 350.

Art Unit: 1647

- 5           LV.    Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IFN- $\gamma$ , classified in class 530, subclass 350.
- LVI.   Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and oncostatin, classified in class 530, subclass 350.
- 10          LVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and TNF- $\alpha$ , classified in class 530, subclass 350.
- LVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and TNF- $\beta$ , classified in class 530, subclass 350.
- LIX.   Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and GM-CSF, classified in class 530, subclass 350.
- 15          LX.    Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and G-CSF, classified in class 530, subclass 350.
- LXI.   Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and M-CSF, classified in class 530, subclass 350.

Art Unit: 1647

LXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and sTNFR, classified in class 530, subclass 350.

LXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-2 and IL-1ra, classified in class 530, subclass 350.

5 LXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-4, classified in class 530, subclass 350.

LXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-5, classified in class 530, subclass 350.

10 LXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-6, classified in class 530, subclass 350.

LXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-7, classified in class 530, subclass 350.

LXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-8, classified in class 530, subclass 350.

15 LXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-10, classified in class 530, subclass 350.

LXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-11, classified in class 530, subclass 350.

Art Unit: 1647

LXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-12, classified in class 530, subclass 350.

LXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IFN- $\alpha$ , classified in class 530, subclass 350.

5 LXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IFN- $\beta$ , classified in class 530, subclass 350.

LXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IFN- $\gamma$ , classified in class 530, subclass 350.

10 LXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and oncostatin, classified in class 530, subclass 350.

LXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and TNF- $\alpha$ , classified in class 530, subclass 350.

LXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and TNF- $\beta$ , classified in class 530, subclass 350.

15 LXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and GM-CSF, classified in class 530, subclass 350.

LXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and G-CSF, classified in class 530, subclass 350.

Art Unit: 1647

- LXXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and M-CSF, classified in class 530, subclass 350.
- LXXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and sTNFR, classified in class 530, subclass 350.
- 5 LXXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-3 and IL-1ra, classified in class 530, subclass 350.
- LXXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-5, classified in class 530, subclass 350.
- 10 LXXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-6, classified in class 530, subclass 350.
- LXXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-7, classified in class 530, subclass 350.
- LXXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-8, classified in class 530, subclass 350.
- 15 LXXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-10, classified in class 530, subclass 350.
- LXXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-11, classified in class 530, subclass 350.



Art Unit: 1647

LXXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-12, classified in class 530, subclass 350.

XC. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IFN- $\alpha$ , classified in class 530, subclass 350.

5 XCI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IFN- $\beta$ , classified in class 530, subclass 350.

XCII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IFN- $\gamma$ , classified in class 530, subclass 350.

10 XCIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and oncostatin, classified in class 530, subclass 350.

XCIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and TNF- $\alpha$ , classified in class 530, subclass 350.

XCV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and TNF- $\beta$ , classified in class 530, subclass 350.

15 XCVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and GM-CSF, classified in class 530, subclass 350.

XCVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and G-CSF, classified in class 530, subclass 350.

Art Unit: 1647

XCVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and M-CSF, classified in class 530, subclass 350.

XCIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and sTNFR, classified in class 530, subclass 350.

5 C. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-4 and IL-1ra, classified in class 530, subclass 350.

CI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IL-6, classified in class 530, subclass 350.

10 CII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IL-7, classified in class 530, subclass 350.

CIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IL-8, classified in class 530, subclass 350.

CIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IL-10, classified in class 530, subclass 350.

15 CV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IL-11, classified in class 530, subclass 350.

CVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IL-12, classified in class 530, subclass 350.

Art Unit: 1647

CVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IFN- $\alpha$ , classified in class 530, subclass 350.

CVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IFN- $\beta$ , classified in class 530, subclass 350.

5 CIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IFN- $\gamma$ , classified in class 530, subclass 350.

CX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and oncostatin, classified in class 530, subclass 350.

10 CXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and TNF- $\alpha$ , classified in class 530, subclass 350.

CXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and TNF- $\beta$ , classified in class 530, subclass 350.

CXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and GM-CSF, classified in class 530, subclass 350.

15 CXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and G-CSF, classified in class 530, subclass 350.

CXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and M-CSF, classified in class 530, subclass 350.

Art Unit: 1647

CXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and sTNFR, classified in class 530, subclass 350.

CXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-5 and IL-1ra, classified in class 530, subclass 350.

5 CXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IL-7, classified in class 530, subclass 350.

CXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IL-8, classified in class 530, subclass 350.

10 CXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IL-10, classified in class 530, subclass 350.

CXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IL-11, classified in class 530, subclass 350.

CXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IL-12, classified in class 530, subclass 350.

15 CXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IFN- $\alpha$ , classified in class 530, subclass 350.

CXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IFN- $\beta$ , classified in class 530, subclass 350.

Art Unit: 1647

- CXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IFN- $\gamma$ , classified in class 530, subclass 350.
- CXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and oncostatin, classified in class 530, subclass 350.
- 5 CXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and TNF- $\alpha$ , classified in class 530, subclass 350.
- CXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and TNF- $\beta$ , classified in class 530, subclass 350.
- CXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition  
10 comprising IL-6 and GM-CSF, classified in class 530, subclass 350.
- CXXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and G-CSF, classified in class 530, subclass 350.
- CXXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and M-CSF, classified in class 530, subclass 350.
- 15 CXXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and sTNFR, classified in class 530, subclass 350.
- CXXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-6 and IL-1ra, classified in class 530, subclass 350.

Art Unit: 1647

- CXXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IL-8, classified in class 530, subclass 350.
- CXXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IL-10, classified in class 530, subclass 350.
- 5 CXXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IL-11, classified in class 530, subclass 350.
- CXXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IL-12, classified in class 530, subclass 350.
- 10 CXXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IFN- $\alpha$ , classified in class 530, subclass 350.
- CXXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IFN- $\beta$ , classified in class 530, subclass 350.
- CXL. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IFN- $\gamma$ , classified in class 530, subclass 350.
- 15 CXLI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and oncostatin, classified in class 530, subclass 350.
- CXLII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and TNF- $\alpha$ , classified in class 530, subclass 350.

Art Unit: 1647

- CXLIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and TNF- $\beta$ , classified in class 530, subclass 350.
- CXLIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and GM-CSF, classified in class 530, subclass 350.
- 5 CXLV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and G-CSF, classified in class 530, subclass 350.
- CXLVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and M-CSF, classified in class 530, subclass 350.
- 10 CXLVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and sTNFR, classified in class 530, subclass 350.
- CXLVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-7 and IL-1ra, classified in class 530, subclass 350.
- CXLIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and IL-10, classified in class 530, subclass 350.
- 15 CL. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and IL-11, classified in class 530, subclass 350.
- CLI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and IL-12, classified in class 530, subclass 350.

Art Unit: 1647

CLII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and IFN- $\alpha$ , classified in class 530, subclass 350.

CLIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and IFN- $\beta$ , classified in class 530, subclass 350.

5 CLIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and IFN- $\gamma$ , classified in class 530, subclass 350.

CLV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and oncostatin, classified in class 530, subclass 350.

10 CLVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and TNF- $\alpha$ , classified in class 530, subclass 350.

CLVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and TNF- $\beta$ , classified in class 530, subclass 350.

CLVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and GM-CSF, classified in class 530, subclass 350.

15 CLIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and G-CSF, classified in class 530, subclass 350.

CLX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and M-CSF, classified in class 530, subclass 350.



Art Unit: 1647

CLXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and sTNFR, classified in class 530, subclass 350.

CLXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-8 and IL-1ra, classified in class 530, subclass 350.

5 CLXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and IL-11, classified in class 530, subclass 350.

CLXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and IL-12, classified in class 530, subclass 350.

10 CLXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and IFN- $\alpha$ , classified in class 530, subclass 350.

CLXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and IFN- $\beta$ , classified in class 530, subclass 350.

CLXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and IFN- $\gamma$ , classified in class 530, subclass 350.

15 CLXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and oncostatin, classified in class 530, subclass 350.

CLXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and TNF- $\alpha$ , classified in class 530, subclass 350.

Art Unit: 1647

- CLXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and TNF- $\beta$ , classified in class 530, subclass 350.
- CLXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and GM-CSF, classified in class 530, subclass 350.
- 5 CLXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and G-CSF, classified in class 530, subclass 350.
- CLXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and M-CSF, classified in class 530, subclass 350.
- 10 CLXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and sTNFR, classified in class 530, subclass 350.
- CLXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-10 and IL-1ra, classified in class 530, subclass 350.
- CLXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and IL-12, classified in class 530, subclass 350.
- 15 CLXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and IFN- $\alpha$ , classified in class 530, subclass 350.
- CLXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and IFN- $\beta$ , classified in class 530, subclass 350.

Art Unit: 1647

- CLXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and IFN- $\gamma$ , classified in class 530, subclass 350.
- CLXXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and oncostatin, classified in class 530, subclass 350.
- 5 CLXXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and TNF- $\alpha$ , classified in class 530, subclass 350.
- CLXXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and TNF- $\beta$ , classified in class 530, subclass 350.
- 10 CLXXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and GM-CSF, classified in class 530, subclass 350.
- CLXXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and G-CSF, classified in class 530, subclass 350.
- CLXXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and M-CSF, classified in class 530, subclass 350.
- 15 CLXXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and sTNFR, classified in class 530, subclass 350.
- CLXXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-11 and IL-1ra, classified in class 530, subclass 350.

Art Unit: 1647

CLXXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and IFN- $\alpha$ , classified in class 530, subclass 350.

CLXXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and IFN- $\beta$ , classified in class 530, subclass 350.

5 CXC. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and IFN- $\gamma$ , classified in class 530, subclass 350.

CXCI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and oncostatin, classified in class 530, subclass 350.

10 CXCII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and TNF- $\alpha$ , classified in class 530, subclass 350.

CXCIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and TNF- $\beta$ , classified in class 530, subclass 350.

CXCIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and GM-CSF, classified in class 530, subclass 350.

15 CXCV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and G-CSF, classified in class 530, subclass 350.

CXCVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and M-CSF, classified in class 530, subclass 350.

Art Unit: 1647

CXCVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and sTNFR, classified in class 530, subclass 350.

CXCVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IL-12 and IL-1ra, classified in class 530, subclass 350.

5 CXCI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and IFN- $\beta$ , classified in class 530, subclass 350.

CC. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and IFN- $\gamma$ , classified in class 530, subclass 350.

10 CCI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and oncostatin, classified in class 530, subclass 350.

CCII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and TNF- $\alpha$ , classified in class 530, subclass 350.

CCIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and TNF- $\beta$ , classified in class 530, subclass 350.

15 CCIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and GM-CSF, classified in class 530, subclass 350.

CCV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and G-CSF, classified in class 530, subclass 350.

Art Unit: 1647

CCVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and M-CSF, classified in class 530, subclass 350.

CCVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and sTNFR, classified in class 530, subclass 350.

5 CCVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\alpha$  and IL-1ra, classified in class 530, subclass 350.

CCIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and IFN- $\gamma$ , classified in class 530, subclass 350.

10 CCX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and oncostatin, classified in class 530, subclass 350.

CCXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and TNF- $\alpha$ , classified in class 530, subclass 350.

CCXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and TNF- $\beta$ , classified in class 530, subclass 350.

15 CCXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and GM-CSF, classified in class 530, subclass 350.

CCXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and G-CSF, classified in class 530, subclass 350.

Art Unit: 1647

- CCXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and M-CSF, classified in class 530, subclass 350.
- CCXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and sTNFR, classified in class 530, subclass 350.
- 5 CCXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\beta$  and IL-1ra, classified in class 530, subclass 350.
- CCXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and oncostatin, classified in class 530, subclass 350.
- 10 CCXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and TNF- $\alpha$ , classified in class 530, subclass 350.
- CCXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and TNF- $\beta$ , classified in class 530, subclass 350.
- CCXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and GM-CSF, classified in class 530, subclass 350.
- 15 CCXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and G-CSF, classified in class 530, subclass 350.
- CCXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and M-CSF, classified in class 530, subclass 350.

Art Unit: 1647

- CCXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and sTNFR, classified in class 530, subclass 350.
- CCXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising IFN- $\gamma$  and IL-1ra, classified in class 530, subclass 350.
- 5 CCXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising oncostatin and TNF- $\alpha$ , classified in class 530, subclass 350.
- CCXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising oncostatin and TNF- $\beta$ , classified in class 530, subclass 350.
- 10 CCXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising oncostatin and GM-CSF, classified in class 530, subclass 350.
- CCXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising oncostatin and G-CSF, classified in class 530, subclass 350.
- CCXXX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising oncostatin and M-CSF, classified in class 530, subclass 350.
- 15 CCXXXI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising oncostatin and sTNFR, classified in class 530, subclass 350.
- CCXXXII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising oncostatin and IL-1ra, classified in class 530, subclass 350.



Art Unit: 1647

- CCXXXIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\alpha$  and TNF- $\beta$ , classified in class 530, subclass 350.
- CCXXXIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\alpha$  and GM-CSF, classified in class 530, subclass 350.
- 5 CCXXXV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\alpha$  and G-CSF, classified in class 530, subclass 350.
- CCXXXVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\alpha$  and M-CSF, classified in class 530, subclass 350.
- 10 CCXXXVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\alpha$  and sTNFR, classified in class 530, subclass 350.
- CCXXXVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\alpha$  and IL-1ra, classified in class 530, subclass 350.
- CCXXXIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\beta$  and GM-CSF, classified in class 530, subclass 350.
- 15 CCXL. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\beta$  and G-CSF, classified in class 530, subclass 350.
- CCXLI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\beta$  and M-CSF, classified in class 530, subclass 350.

Art Unit: 1647

- CCXLII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\beta$  and sTNFR, classified in class 530, subclass 350.
- CCXLIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising TNF- $\beta$  and IL-1ra, classified in class 530, subclass 350.
- 5 CCXLIV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising GM-CSF and G-CSF, classified in class 530, subclass 350.
- CCXLV. Claim(s) 1-10, to the extent that they are drawn to a composition comprising GM-CSF and M-CSF, classified in class 530, subclass 350.
- 10 CCXLVI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising GM-CSF and sTNFR, classified in class 530, subclass 350.
- CCXLVII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising GM-CSF and IL-1ra, classified in class 530, subclass 350.
- CCXLVIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising G-CSF and M-CSF, classified in class 530, subclass 350.
- 15 CCXLIX. Claim(s) 1-10, to the extent that they are drawn to a composition comprising G-CSF and sTNFR, classified in class 530, subclass 350.
- CCL. Claim(s) 1-10, to the extent that they are drawn to a composition comprising G-CSF and IL-1ra, classified in class 530, subclass 350.

Art Unit: 1647

CCLI. Claim(s) 1-10, to the extent that they are drawn to a composition comprising M-CSF and sTNFR, classified in class 530, subclass 350.

CCLII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising M-CSF and IL-1ra, classified in class 530, subclass 350.

5 CCLIII. Claim(s) 1-10, to the extent that they are drawn to a composition comprising sTNFR and IL-1ra, classified in class 530, subclass 350.

AA  
12/16/11  
10 CCLIV. Claim(s) ~~11~~<sup>12</sup>-21, to the extent that they are drawn to a method of producing a mixture of cytokines comprising transforming a cell line with a PKR gene such the PKR is overproduced, classified in class 435, subclass 69.2.

CCLV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-1- $\beta$ , classified in class 514, subclass 12.

15 CCLVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-2, classified in class 514, subclass 12.

Art Unit: 1647

CCLVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-3, classified in class 514, subclass 12.

5 CCLVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-4, classified in class 514, subclass 12.

CCLIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-5, classified in class 514, subclass 12.

10 CCLX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-6, classified in class 514, subclass 12.

15 CCLXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-7, classified in class 514, subclass 12.

CCLXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-8, classified in class 514, subclass 12.

Art Unit: 1647

CCLXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-10, classified in class 514, subclass 12.

5 CCLXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-11, classified in class 514, subclass 12.

CCLXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-12, classified in class 514, subclass 12.

10 CCLXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\alpha$ , classified in class 514, subclass 12.

15 CCLXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\beta$ , classified in class 514, subclass 12.

CCLXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\gamma$ , classified in class 514, subclass 12.

Art Unit: 1647

CCLXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and oncostatin, classified in class 514, subclass 12.

5 CCLXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and TNF- $\alpha$ , classified in class 514, subclass 12.

CCLXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.

10 CCLXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and GM-CSF, classified in class 514, subclass 12.

CCLXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and G-CSF, classified in class 514, subclass 12.

15 CCLXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CCLXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and sTNFR, classified in class 514, subclass 12.

5 CCLXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\alpha$  and IL-1ra, classified in class 514, subclass 12.

CCLXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-2, classified in class 514, subclass 12.

10 CCLXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-3, classified in class 514, subclass 12.

CCLXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-4, classified in class 514, subclass 12.

15 CCLXXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-5, classified in class 514, subclass 12.

Art Unit: 1647

CCLXXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-6, classified in class 514, subclass 12.

5 CCLXXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-7, classified in class 514, subclass 12.

CCLXXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-8, classified in class 514, subclass 12.

10 CCLXXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-10, classified in class 514, subclass 12.

15 CCLXXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-11, classified in class 514, subclass 12.

CCLXXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-12, classified in class 514, subclass 12.



Art Unit: 1647

CCLXXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IFN- $\alpha$ , classified in class 514, subclass 12.

CCLXXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IFN- $\beta$ , classified in class 514, subclass 12.

CCLXXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IFN- $\gamma$ , classified in class 514, subclass 12.

CCXC. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and oncostatin, classified in class 514, subclass 12.

CCXCI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and TNF- $\alpha$ , classified in class 514, subclass 12.

CCXCII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and TNF- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

CCXCIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and GM-CSF, classified in class 514, subclass 12.

5 CCXCIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and G-CSF, classified in class 514, subclass 12.

CCXCV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and M-CSF, classified in class 514, subclass 12.

10 CCXCVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and sTNFR, classified in class 514, subclass 12.

15 CCXCVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-1- $\beta$  and IL-1ra, classified in class 514, subclass 12.

CCXCVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-3, classified in class 514, subclass 12.

Art Unit: 1647

CCXCIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-4, classified in class 514, subclass 12.

CCC. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-5, classified in class 514, subclass 12.

CCCI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-6, classified in class 514, subclass 12.

CCCII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-7, classified in class 514, subclass 12.

CCCIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-8, classified in class 514, subclass 12.

CCCIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-10, classified in class 514, subclass 12.

Art Unit: 1647

- CCCV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-11, classified in class 514, subclass 12.
- 5 CCCVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-12, classified in class 514, subclass 12.
- CCCVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IFN- $\alpha$ , classified in class 514, subclass 12.
- 10 CCCVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IFN- $\beta$ , classified in class 514, subclass 12.
- CCCIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IFN- $\gamma$ ,  
15 classified in class 514, subclass 12.
- CCCX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

CCCXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and TNF- $\alpha$ , classified in class 514, subclass 12.

CCCXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and TNF- $\beta$ , classified in class 514, subclass 12.

CCCXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and GM-CSF, classified in class 514, subclass 12.

CCCXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and G-CSF, classified in class 514, subclass 12.

CCCXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and M-CSF, classified in class 514, subclass 12.

CCCXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

CCCXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-2 and IL-1ra, classified in class 514, subclass 12.

CCCXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-4, classified in class 514, subclass 12.

CCCXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-5, classified in class 514, subclass 12.

CCCXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-6, classified in class 514, subclass 12.

CCCXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-7, classified in class 514, subclass 12.

CCCXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-8, classified in class 514, subclass 12.

Art Unit: 1647

CCCXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-10, classified in class 514, subclass 12.

CCCXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-11, classified in class 514, subclass 12.

CCCXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-12, classified in class 514, subclass 12.

CCCXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IFN- $\alpha$ , classified in class 514, subclass 12.

CCCXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IFN- $\beta$ , classified in class 514, subclass 12.

CCCXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IFN- $\gamma$ , classified in class 514, subclass 12.

Art Unit: 1647

CCCXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and oncostatin, classified in class 514, subclass 12.

5 CCCXXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and TNF- $\alpha$ , classified in class 514, subclass 12.

CCCXXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and TNF- $\beta$ , classified in class 514, subclass 12.

10 CCCXXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and GM-CSF, classified in class 514, subclass 12.

15 CCCXXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and G-CSF, classified in class 514, subclass 12.

CCCXXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and M-CSF, classified in class 514, subclass 12.



Art Unit: 1647

CCCCXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and sTNFR, classified in class 514, subclass 12.

CCCCXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-3 and IL-1ra, classified in class 514, subclass 12.

CCCCXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-5, classified in class 514, subclass 12.

CCCCXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-6, classified in class 514, subclass 12.

CCCCXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-7, classified in class 514, subclass 12.

CCCCXL. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-8, classified in class 514, subclass 12.

Art Unit: 1647

- CCCXLI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-10, classified in class 514, subclass 12.
- 5 CCCXLII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-11, classified in class 514, subclass 12.
- CCCXLIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-12, classified in class 514, subclass 12.
- 10 CCCXLIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IFN- $\alpha$ , classified in class 514, subclass 12.
- CCCXLV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IFN- $\beta$ , classified in class 514, subclass 12.
- 15 CCCXLVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IFN- $\gamma$ , classified in class 514, subclass 12.

Art Unit: 1647

CCCXLVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and oncostatin, classified in class 514, subclass 12.

5 CCCXLVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and TNF- $\alpha$ , classified in class 514, subclass 12.

CCCXLIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and TNF- $\beta$ , classified in class 514, subclass 12.

10 CCCL. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and GM-CSF, classified in class 514, subclass 12.

CCCLI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and G-CSF, 15 classified in class 514, subclass 12.

CCCLII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CCCLIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and sTNFR, classified in class 514, subclass 12.

5 CCCLIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-4 and IL-1ra, classified in class 514, subclass 12.

CCCLV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IL-6, classified in class 514, subclass 12.

10 CCCLVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IL-7, classified in class 514, subclass 12.

15 CCCLVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IL-8, classified in class 514, subclass 12.

CCCLVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IL-10, classified in class 514, subclass 12.

Art Unit: 1647

- CCCLIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IL-11, classified in class 514, subclass 12.
- 5 CCCLX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IL-12, classified in class 514, subclass 12.
- CCCLXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IFN- $\alpha$ , classified in class 514, subclass 12.
- 10 CCCLXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IFN- $\beta$ , classified in class 514, subclass 12.
- CCCLXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IFN- $\gamma$ , classified in class 514, subclass 12.
- 15 CCCLXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

CCCLXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and TNF- $\alpha$ , classified in class 514, subclass 12.

CCCLXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and TNF- $\beta$ , classified in class 514, subclass 12.

CCCLXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and GM-CSF, classified in class 514, subclass 12.

CCCLXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and G-CSF, classified in class 514, subclass 12.

CCCLXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and M-CSF, classified in class 514, subclass 12.

CCCLXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

CCCLXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-5 and IL-1ra, classified in class 514, subclass 12.

CCCLXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IL-7, classified in class 514, subclass 12.

CCCLXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IL-8, classified in class 514, subclass 12.

CCCLXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IL-10, classified in class 514, subclass 12.

CCCLXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IL-11, classified in class 514, subclass 12.

CCCLXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IL-12, classified in class 514, subclass 12.

Art Unit: 1647

CCCLXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IFN- $\alpha$ , classified in class 514, subclass 12.

CCCLXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IFN- $\beta$ , classified in class 514, subclass 12.

CCCLXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IFN- $\gamma$ , classified in class 514, subclass 12.

CCCLXXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and oncostatin, classified in class 514, subclass 12.

CCCLXXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and TNF- $\alpha$ , classified in class 514, subclass 12.

CCCLXXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and TNF- $\beta$ , classified in class 514, subclass 12.



Art Unit: 1647

CCCLXXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and GM-CSF, classified in class 514, subclass 12.

CCCLXXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and G-CSF, classified in class 514, subclass 12.

CCCLXXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and M-CSF, classified in class 514, subclass 12.

CCCLXXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and sTNFR, classified in class 514, subclass 12.

CCCLXXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-6 and IL-1ra, classified in class 514, subclass 12.

CCCLXXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IL-8, classified in class 514, subclass 12.

Art Unit: 1647

CCCLXXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IL-10, classified in class 514, subclass 12.

CCCXC. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IL-11, classified in class 514, subclass 12.

CCCXCI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IL-12, classified in class 514, subclass 12.

CCCXCII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IFN- $\alpha$ , classified in class 514, subclass 12.

CCCXCIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IFN- $\beta$ , classified in class 514, subclass 12.

CCCXCIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IFN- $\gamma$ , classified in class 514, subclass 12.

Art Unit: 1647

CCCXCV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and oncostatin, classified in class 514, subclass 12.

CCCXCVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and TNF- $\alpha$ , classified in class 514, subclass 12.

CCCXCVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and TNF- $\beta$ , classified in class 514, subclass 12.

CCCXCVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and GM-CSF, classified in class 514, subclass 12.

CCCXCIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and G-CSF, classified in class 514, subclass 12.

CD. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CDI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and sTNFR, classified in class 514, subclass 12.

CDII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-7 and IL-1ra, classified in class 514, subclass 12.

CDIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and IL-10, classified in class 514, subclass 12.

CDIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and IL-11, classified in class 514, subclass 12.

CDV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and IL-12, classified in class 514, subclass 12.

CDVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and IFN- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

CDVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and IFN- $\beta$ , classified in class 514, subclass 12.

CDVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and IFN- $\gamma$ , classified in class 514, subclass 12.

CDIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and oncostatin, classified in class 514, subclass 12.

CDX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and TNF- $\alpha$ , classified in class 514, subclass 12.

CDXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and TNF- $\beta$ , classified in class 514, subclass 12.

CDXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CDXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and G-CSF, classified in class 514, subclass 12.

CDXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and M-CSF, classified in class 514, subclass 12.

CDXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and sTNFR, classified in class 514, subclass 12.

CDXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-8 and IL-1ra, classified in class 514, subclass 12.

CDXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and IL-11, classified in class 514, subclass 12.

CDXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and IL-12, classified in class 514, subclass 12.

Art Unit: 1647

CDXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and IFN- $\alpha$ , classified in class 514, subclass 12.

CDXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and IFN- $\beta$ , classified in class 514, subclass 12.

CDXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and IFN- $\gamma$ , classified in class 514, subclass 12.

CDXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and oncostatin, classified in class 514, subclass 12.

CDXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and TNF- $\alpha$ , classified in class 514, subclass 12.

CDXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and TNF- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

CDXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and GM-CSF, classified in class 514, subclass 12.

CDXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and G-CSF, classified in class 514, subclass 12.

CDXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and M-CSF, classified in class 514, subclass 12.

CDXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and sTNFR, classified in class 514, subclass 12.

CDXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-10 and IL-1ra, classified in class 514, subclass 12.

CDXXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and IL-12, classified in class 514, subclass 12.



Art Unit: 1647

CDXXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and IFN- $\alpha$ , classified in class 514, subclass 12.

CDXXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and IFN- $\beta$ , classified in class 514, subclass 12.

CDXXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and IFN- $\gamma$ , classified in class 514, subclass 12.

CDXXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and oncostatin, classified in class 514, subclass 12.

CDXXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and TNF- $\alpha$ , classified in class 514, subclass 12.

CDXXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and TNF- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

CDXXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and GM-CSF, classified in class 514, subclass 12.

CDXXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and G-CSF, classified in class 514, subclass 12.

CDXXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and M-CSF, classified in class 514, subclass 12.

CDXL. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and sTNFR, classified in class 514, subclass 12.

CDXLI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-11 and IL-1ra, classified in class 514, subclass 12.

CDXLII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and IFN- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

CDXLIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and IFN- $\beta$ , classified in class 514, subclass 12.

CDXLIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and IFN- $\gamma$ , classified in class 514, subclass 12.

CDXLV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and oncostatin, classified in class 514, subclass 12.

CDXLVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and TNF- $\alpha$ , classified in class 514, subclass 12.

CDXLVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and TNF- $\beta$ , classified in class 514, subclass 12.

CDXLVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CDXLIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and G-CSF, classified in class 514, subclass 12.

CDL. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and M-CSF, classified in class 514, subclass 12.

CDLI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and sTNFR, classified in class 514, subclass 12.

CDLII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IL-12 and IL-1ra, classified in class 514, subclass 12.

CDLIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and IFN- $\beta$ , classified in class 514, subclass 12.

CDLIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and IFN- $\gamma$ , classified in class 514, subclass 12.

Art Unit: 1647

- CDLV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and oncostatin, classified in class 514, subclass 12.
- 5 CDLVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and TNF- $\alpha$ , classified in class 514, subclass 12.
- CDLVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.
- 10 CDLVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and GM-CSF, classified in class 514, subclass 12.
- CDLIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and G-CSF, classified in class 514, subclass 12.
- 15 CDLX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

- CDLXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and sTNFR, classified in class 514, subclass 12.
- 5 CDLXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\alpha$  and IL-1ra, classified in class 514, subclass 12.
- CDLXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and IFN- $\gamma$ , classified in class 514, subclass 12.
- 10 CDLXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and oncostatin, classified in class 514, subclass 12.
- CDLXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and TNF- $\alpha$ ,  
15 classified in class 514, subclass 12.
- CDLXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and TNF- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

CDLXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and GM-CSF, classified in class 514, subclass 12.

CDLXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and G-CSF, classified in class 514, subclass 12.

CDLXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and M-CSF, classified in class 514, subclass 12.

CDLXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and sTNFR, classified in class 514, subclass 12.

CDLXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\beta$  and IL-1ra, classified in class 514, subclass 12.

CDLXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

CDLXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and TNF- $\alpha$ , classified in class 514, subclass 12.

CDLXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and TNF- $\beta$ , classified in class 514, subclass 12.

CDLXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and GM-CSF, classified in class 514, subclass 12.

CDLXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and G-CSF, classified in class 514, subclass 12.

CDLXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and M-CSF, classified in class 514, subclass 12.

CDLXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and sTNFR, classified in class 514, subclass 12.



Art Unit: 1647

CDLXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising IFN- $\gamma$  and IL-1ra, classified in class 514, subclass 12.

CDLXXX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising oncostatin and TNF- $\alpha$ , classified in class 514, subclass 12.

CDLXXXI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising oncostatin and TNF- $\beta$ , classified in class 514, subclass 12.

CDLXXXII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising oncostatin and GM-CSF, classified in class 514, subclass 12.

CDLXXXIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising oncostatin and G-CSF, classified in class 514, subclass 12.

CDLXXXIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising oncostatin and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CDLXXXV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising oncostatin and sTNFR, classified in class 514, subclass 12.

CDLXXXVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising oncostatin and IL-1ra, classified in class 514, subclass 12.

CDLXXXVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.

CDLXXXVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\alpha$  and GM-CSF, classified in class 514, subclass 12.

CDLXXXIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\alpha$  and G-CSF, classified in class 514, subclass 12.

CDXC. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\alpha$  and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

- CDXCI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\alpha$  and sTNFR, classified in class 514, subclass 12.
- 5 CDXCII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\alpha$  and IL-1ra, classified in class 514, subclass 12.
- CDXCIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\beta$  and GM-CSF, classified in class 514, subclass 12.
- 10 CDXCIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\beta$  and G-CSF, classified in class 514, subclass 12.
- CDXCV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\beta$  and M-CSF, classified in class 514, subclass 12.
- 15 CDXCVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\beta$  and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

CDXCVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising TNF- $\beta$  and IL-1ra, classified in class 514, subclass 12.

CDXCVIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising GM-CSF and G-CSF, classified in class 514, subclass 12.

CDXCIX. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising GM-CSF and M-CSF, classified in class 514, subclass 12.

D. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising GM-CSF and sTNFR, classified in class 514, subclass 12.

DI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising GM-CSF and IL-1ra, classified in class 514, subclass 12.

DII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising G-CSF and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DIII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising G-CSF and sTNFR, classified in class 514, subclass 12.

DIV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising G-CSF and IL-1ra, classified in class 514, subclass 12.

DV. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising M-CSF and sTNFR, classified in class 514, subclass 12.

DVI. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising M-CSF and IL-1ra, classified in class 514, subclass 12.

DVII. Claim(s) 22, to the extent that it is drawn to a method of treating cancer comprising administering a composition comprising sTNFR and IL-1ra, classified in class 514, subclass 12.

DVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-1- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-2, classified in class 514, subclass 12.

DX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-3, classified in class 514, subclass 12.

DXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-4, classified in class 514, subclass 12.

DXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-5, classified in class 514, subclass 12.

DXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-6, classified in class 514, subclass 12.

DXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-7, classified in class 514, subclass 12.

Art Unit: 1647

DXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-8, classified in class 514, subclass 12.

DXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-10, classified in class 514, subclass 12.

DXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-11, classified in class 514, subclass 12.

DXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-12, classified in class 514, subclass 12.

DXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\alpha$ , classified in class 514, subclass 12.

DXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

- 5 DXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\gamma$ , classified in class 514, subclass 12.
- 5 DXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and oncostatin, classified in class 514, subclass 12.
- 10 DXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and TNF- $\alpha$ , classified in class 514, subclass 12.
- 10 DXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.
- 15 DXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and GM-CSF, classified in class 514, subclass 12.
- DXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and G-CSF, classified in class 514, subclass 12.



Art Unit: 1647

DXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and M-CSF, classified in class 514, subclass 12.

5 DXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and sTNFR, classified in class 514, subclass 12.

DXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\alpha$  and IL-1ra, classified in class 514, subclass 12.

10 DXXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-2, classified in class 514, subclass 12.

15 DXXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-3, classified in class 514, subclass 12.

DXXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-4, classified in class 514, subclass 12.

Art Unit: 1647

DXXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-5, classified in class 514, subclass 12.

5 DXXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-6, classified in class 514, subclass 12.

DXXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-7, classified in class 514, subclass 12.

10 DXXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-8, classified in class 514, subclass 12.

15 DXXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-10, classified in class 514, subclass 12.

DXXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-11, classified in class 514, subclass 12.

Art Unit: 1647

DXXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-12, classified in class 514, subclass 12.

DXL. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IFN- $\alpha$ , classified in class 514, subclass 12.

DXLI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IFN- $\beta$ , classified in class 514, subclass 12.

DXLII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IFN- $\gamma$ , classified in class 514, subclass 12.

DXLIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and oncostatin, classified in class 514, subclass 12.

DXLIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and TNF- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

DXLV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and TNF- $\beta$ , classified in class 514, subclass 12.

DXLVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and GM-CSF, classified in class 514, subclass 12.

DXLVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and G-CSF, classified in class 514, subclass 12.

DXLVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and M-CSF, classified in class 514, subclass 12.

DXLIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and sTNFR, classified in class 514, subclass 12.

DL. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-1- $\beta$  and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

DLI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-3, classified in class 514, subclass 12.

DLII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-4, classified in class 514, subclass 12.

DLIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-5, classified in class 514, subclass 12.

DLIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-6, classified in class 514, subclass 12.

DLV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-7, classified in class 514, subclass 12.

DLVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-8, classified in class 514, subclass 12.

Art Unit: 1647

DLVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-10, classified in class 514, subclass 12.

DLVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-11, classified in class 514, subclass 12.

DLIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-12, classified in class 514, subclass 12.

DLX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IFN- $\alpha$ , classified in class 514, subclass 12.

DLXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IFN- $\beta$ , classified in class 514, subclass 12.

DLXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IFN- $\gamma$ , classified in class 514, subclass 12.

Art Unit: 1647

DLXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and oncostatin, classified in class 514, subclass 12.

DLXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and TNF- $\alpha$ , classified in class 514, subclass 12.

DLXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and TNF- $\beta$ , classified in class 514, subclass 12.

DLXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and GM-CSF, classified in class 514, subclass 12.

DLXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and G-CSF, classified in class 514, subclass 12.

DLXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DLXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and sTNFR, classified in class 514, subclass 12.

DLXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-2 and IL-1ra, classified in class 514, subclass 12.

DLXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-4, classified in class 514, subclass 12.

DLXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-5, classified in class 514, subclass 12.

DLXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-6, classified in class 514, subclass 12.

DLXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-7, classified in class 514, subclass 12.



Art Unit: 1647

DLXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-8, classified in class 514, subclass 12.

DLXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-10, classified in class 514, subclass 12.

DLXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-11, classified in class 514, subclass 12.

DLXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-12, classified in class 514, subclass 12.

DLXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IFN- $\alpha$ , classified in class 514, subclass 12.

DLXXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IFN- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DLXXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IFN- $\gamma$ , classified in class 514, subclass 12.

DLXXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and oncostatin, classified in class 514, subclass 12.

DLXXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and TNF- $\alpha$ , classified in class 514, subclass 12.

DLXXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and TNF- $\beta$ , classified in class 514, subclass 12.

DLXXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and GM-CSF, classified in class 514, subclass 12.

DLXXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DLXXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and M-CSF, classified in class 514, subclass 12.

DLXXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and sTNFR, classified in class 514, subclass 12.

DLXXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-3 and IL-1ra, classified in class 514, subclass 12.

DXC. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-5, classified in class 514, subclass 12.

DXCI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-6, classified in class 514, subclass 12.

DXCII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-7, classified in class 514, subclass 12.

Art Unit: 1647

DXCIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-8, classified in class 514, subclass 12.

DXCIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-10, classified in class 514, subclass 12.

DXCV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-11, classified in class 514, subclass 12.

DXCVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-12, classified in class 514, subclass 12.

DXCVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IFN- $\alpha$ , classified in class 514, subclass 12.

DXCVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IFN- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DXCIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IFN- $\gamma$ , classified in class 514, subclass 12.

DC. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and oncostatin, classified in class 514, subclass 12.

DCI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and TNF- $\alpha$ , classified in class 514, subclass 12.

DCII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and TNF- $\beta$ , classified in class 514, subclass 12.

DCIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and GM-CSF, classified in class 514, subclass 12.

DCIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and M-CSF, classified in class 514, subclass 12.

DCVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and sTNFR, classified in class 514, subclass 12.

DCVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-4 and IL-1ra, classified in class 514, subclass 12.

DCVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IL-6, classified in class 514, subclass 12.

DCIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IL-7, classified in class 514, subclass 12.

DCX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IL-8, classified in class 514, subclass 12.

Art Unit: 1647

DCXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IL-10, classified in class 514, subclass 12.

DCXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IL-11, classified in class 514, subclass 12.

DCXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IL-12, classified in class 514, subclass 12.

DCXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IFN- $\alpha$ , classified in class 514, subclass 12.

DCXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IFN- $\beta$ , classified in class 514, subclass 12.

DCXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IFN- $\gamma$ , classified in class 514, subclass 12.

Art Unit: 1647

DCXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and oncostatin, classified in class 514, subclass 12.

DCXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and TNF- $\alpha$ , classified in class 514, subclass 12.

DCXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and TNF- $\beta$ , classified in class 514, subclass 12.

DCXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and GM-CSF, classified in class 514, subclass 12.

DCXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and G-CSF, classified in class 514, subclass 12.

DCXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and M-CSF, classified in class 514, subclass 12.



Art Unit: 1647

DCXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and sTNFR, classified in class 514, subclass 12.

DCXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-5 and IL-1ra, classified in class 514, subclass 12.

DCXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IL-7, classified in class 514, subclass 12.

DCXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IL-8, classified in class 514, subclass 12.

DCXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IL-10, classified in class 514, subclass 12.

DCXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IL-11, classified in class 514, subclass 12.

Art Unit: 1647

DCXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IL-12, classified in class 514, subclass 12.

DCXXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IFN- $\alpha$ , classified in class 514, subclass 12.

DCXXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IFN- $\beta$ , classified in class 514, subclass 12.

DCXXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IFN- $\gamma$ , classified in class 514, subclass 12.

DCXXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and oncostatin, classified in class 514, subclass 12.

DCXXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and TNF- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

DCXXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and TNF- $\beta$ , classified in class 514, subclass 12.

DCXXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and GM-CSF, classified in class 514, subclass 12.

DCXXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and G-CSF, classified in class 514, subclass 12.

DCXXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and M-CSF, classified in class 514, subclass 12.

DCXXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and sTNFR, classified in class 514, subclass 12.

DCXL. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-6 and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

DCXLI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IL-8, classified in class 514, subclass 12.

DCXLII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IL-10, classified in class 514, subclass 12.

DCXLIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IL-11, classified in class 514, subclass 12.

DCXLIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IL-12, classified in class 514, subclass 12.

DCXLV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IFN- $\alpha$ , classified in class 514, subclass 12.

DCXLVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IFN- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DCXLVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IFN- $\gamma$ , classified in class 514, subclass 12.

DCXLVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and oncostatin, classified in class 514, subclass 12.

DCXLIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and TNF- $\alpha$ , classified in class 514, subclass 12.

DCL. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and TNF- $\beta$ , classified in class 514, subclass 12.

DCLI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and GM-CSF, classified in class 514, subclass 12.

DCLII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCLIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and M-CSF, classified in class 514, subclass 12.

5 DCLIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and sTNFR, classified in class 514, subclass 12.

DCLV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-7 and IL-1ra, classified in class 514, subclass 12.

10 DCLVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and IL-10, classified in class 514, subclass 12.

15 DCLVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and IL-11, classified in class 514, subclass 12.

DCLVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and IL-12, classified in class 514, subclass 12.

Art Unit: 1647

DCLIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and IFN- $\alpha$ , classified in class 514, subclass 12.

5 DCLX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and IFN- $\beta$ , classified in class 514, subclass 12.

DCLXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and IFN- $\gamma$ , classified in class 514, subclass 12.

10 DCLXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and oncostatin, classified in class 514, subclass 12.

15 DCLXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and TNF- $\alpha$ , classified in class 514, subclass 12.

DCLXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and TNF- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DCLXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and GM-CSF, classified in class 514, subclass 12.

5 DCLXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and G-CSF, classified in class 514, subclass 12.

DCLXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and M-CSF, classified in class 514, subclass 12.

10 DCLXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and sTNFR, classified in class 514, subclass 12.

15 DCLXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-8 and IL-1ra, classified in class 514, subclass 12.

DCLXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and IL-11, classified in class 514, subclass 12.



Art Unit: 1647

DCLXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and IL-12, classified in class 514, subclass 12.

5 DCLXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and IFN- $\alpha$ , classified in class 514, subclass 12.

DCLXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and IFN- $\beta$ , classified in class 514, subclass 12.

10 DCLXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and IFN- $\gamma$ , classified in class 514, subclass 12.

15 DCLXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and oncostatin, classified in class 514, subclass 12.

DCLXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and TNF- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

DCLXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and TNF- $\beta$ , classified in class 514, subclass 12.

5 DCLXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and GM-CSF, classified in class 514, subclass 12.

DCLXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and G-CSF, classified in class 514, subclass 12.

10 DCLXXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and M-CSF, classified in class 514, subclass 12.

15 DCLXXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and sTNFR, classified in class 514, subclass 12.

DCLXXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-10 and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

DCLXXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and IL-12, classified in class 514, subclass 12.

5 DCLXXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and IFN- $\alpha$ , classified in class 514, subclass 12.

DCLXXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and IFN- $\beta$ , classified in class 514, subclass 12.

10 DCLXXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and IFN- $\gamma$ , classified in class 514, subclass 12.

15 DCLXXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and oncostatin, classified in class 514, subclass 12.

DCLXXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and TNF- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

DCLXXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and TNF- $\beta$ , classified in class 514, subclass 12.

DCXC. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and GM-CSF, classified in class 514, subclass 12.

DCXCI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and G-CSF, classified in class 514, subclass 12.

DCXCII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and M-CSF, classified in class 514, subclass 12.

DCXCIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and sTNFR, classified in class 514, subclass 12.

DCXCIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-11 and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

DCXCV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and IFN- $\alpha$ , classified in class 514, subclass 12.

5 DCXCVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and IFN- $\beta$ , classified in class 514, subclass 12.

DCXCVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and IFN- $\gamma$ , classified in class 514, subclass 12.

10 DCXCVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and oncostatin, classified in class 514, subclass 12.

15 DCXCIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and TNF- $\alpha$ , classified in class 514, subclass 12.

DCC. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and TNF- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DCCI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and GM-CSF, classified in class 514, subclass 12.

5 DCCII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and G-CSF, classified in class 514, subclass 12.

DCCIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and M-CSF, classified in class 514, subclass 12.

10 DCCIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and sTNFR, classified in class 514, subclass 12.

15 DCCV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IL-12 and IL-1ra, classified in class 514, subclass 12.

DCCVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and IFN- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DCCVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and IFN- $\gamma$ , classified in class 514, subclass 12.

5 DCCVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and oncostatin, classified in class 514, subclass 12.

DCCIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and TNF- $\alpha$ , classified in class 514, subclass 12.

10 DCCX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.

15 DCCXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and GM-CSF, classified in class 514, subclass 12.

DCCXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and M-CSF, classified in class 514, subclass 12.

5 DCCXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and sTNFR, classified in class 514, subclass 12.

DCCXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\alpha$  and IL-1ra, classified in class 514, subclass 12.

10 DCCXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and IFN- $\gamma$ , classified in class 514, subclass 12.

15 DCCXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and oncostatin, classified in class 514, subclass 12.

DCCXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and TNF- $\alpha$ , classified in class 514, subclass 12.



Art Unit: 1647

DCCXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and TNF- $\beta$ , classified in class 514, subclass 12.

DCCXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and GM-CSF, classified in class 514, subclass 12.

DCCXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and G-CSF, classified in class 514, subclass 12.

DCCXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and M-CSF, classified in class 514, subclass 12.

DCCXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and sTNFR, classified in class 514, subclass 12.

DCCXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\beta$  and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

DCCXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and oncostatin, classified in class 514, subclass 12.

DCCXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and TNF- $\alpha$ , classified in class 514, subclass 12.

DCCXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and TNF- $\beta$ , classified in class 514, subclass 12.

DCCXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and GM-CSF, classified in class 514, subclass 12.

DCCXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and G-CSF, classified in class 514, subclass 12.

DCCXXX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCXXXI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and sTNFR, classified in class 514, subclass 12.

5 DCCXXXII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising IFN- $\gamma$  and IL-1ra, classified in class 514, subclass 12.

DCCXXXIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising oncostatin and TNF- $\alpha$ , classified in class 514, subclass 12.

10 DCCXXXIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising oncostatin and TNF- $\beta$ , classified in class 514, subclass 12.

15 DCCXXXV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising oncostatin and GM-CSF, classified in class 514, subclass 12.

DCCXXXVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising oncostatin and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCXXXVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising oncostatin and M-CSF, classified in class 514, subclass 12.

5 DCCXXXVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising oncostatin and sTNFR, classified in class 514, subclass 12.

DCCXXXIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising oncostatin and IL-1ra, classified in class 514, subclass 12.

10 DCCXL. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.

15 DCCXLI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\alpha$  and GM-CSF, classified in class 514, subclass 12.

DCCXLII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\alpha$  and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCXLIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\alpha$  and M-CSF, classified in class 514, subclass 12.

5 DCCXLIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\alpha$  and sTNFR, classified in class 514, subclass 12.

DCCXLV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\alpha$  and IL-1ra, classified in class 514, subclass 12.

10 DCCXLVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\beta$  and GM-CSF, classified in class 514, subclass 12.

15 DCCXLVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\beta$  and G-CSF, classified in class 514, subclass 12.

DCCXLVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\beta$  and M-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCXLIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\beta$  and sTNFR, classified in class 514, subclass 12.

5 DCCL. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising TNF- $\beta$  and IL-1ra, classified in class 514, subclass 12.

DCCLI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising GM-CSF and G-CSF, classified in class 514, subclass 12.

10 DCCLII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising GM-CSF and M-CSF, classified in class 514, subclass 12.

15 DCCLIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising GM-CSF and sTNFR, classified in class 514, subclass 12.

DCCLIV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising GM-CSF and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

- DCCLV. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising G-CSF and M-CSF, classified in class 514, subclass 12.
- 5 DCCLVI. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising G-CSF and sTNFR, classified in class 514, subclass 12.
- DCCLVII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising G-CSF and IL-1ra, classified in class 514, subclass 12.
- 10 DCCLVIII. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising M-CSF and sTNFR, classified in class 514, subclass 12.
- DCCLIX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising M-CSF and IL-1ra, classified in class 514, subclass 12.
- 15 DCCLX. Claim(s) 23, to the extent that it is drawn to a method of treating a viral infection comprising administering a composition comprising sTNFR and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

DCCLX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-1- $\beta$ , classified in class 514, subclass 12.

DCCLXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-2, classified in class 514, subclass 12.

DCCLXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-3, classified in class 514, subclass 12.

DCCLXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-4, classified in class 514, subclass 12.

DCCLXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-5, classified in class 514, subclass 12.

DCCLXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-6, classified in class 514, subclass 12.



Art Unit: 1647

DCCLXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-7, classified in class 514, subclass 12.

5 DCCLXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-8, classified in class 514, subclass 12.

DCCLXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-10, classified in class 514, subclass 12.

10 DCCLXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-11, classified in class 514, subclass 12.

DCCLXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-12, classified in class 514, subclass 12.

15 DCCLXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

DCCLXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\beta$ , classified in class 514, subclass 12.

DCCLXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IFN- $\gamma$ , classified in class 514, subclass 12.

DCCLXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and oncostatin, classified in class 514, subclass 12.

DCCLXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and TNF- $\alpha$ , classified in class 514, subclass 12.

DCCLXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.

DCCLXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCLXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and G-CSF, classified in class 514, subclass 12.

DCCLXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and M-CSF, classified in class 514, subclass 12.

DCCLXXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and sTNFR, classified in class 514, subclass 12.

DCCLXXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\alpha$  and IL-1ra, classified in class 514, subclass 12.

DCCLXXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-2, classified in class 514, subclass 12.

DCCLXXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-3, classified in class 514, subclass 12.

Art Unit: 1647

- DCCLXXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-4, classified in class 514, subclass 12.
- 5 DCCLXXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-5, classified in class 514, subclass 12.
- DCCLXXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-6, classified in class 514, subclass 12.
- 10 DCCLXXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-7, classified in class 514, subclass 12.
- DCCLXXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-8, classified in class 514, subclass 12.
- 15 DCCLXXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-10, classified in class 514, subclass 12.

Art Unit: 1647

DCCXC. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-11, classified in class 514, subclass 12.

5 DCCXCI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-12, classified in class 514, subclass 12.

DCCXCII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IFN- $\alpha$ , classified in class 514, subclass 12.

10 DCCXCIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IFN- $\beta$ , classified in class 514, subclass 12.

15 DCCXCIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IFN- $\gamma$ , classified in class 514, subclass 12.

DCCXCV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

- DCCXCVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and TNF- $\alpha$ , classified in class 514, subclass 12.
- 5 DCCXCVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and TNF- $\beta$ , classified in class 514, subclass 12.
- DCCXCVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and GM-CSF, classified in class 514, subclass 12.
- 10 DCCXCIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and G-CSF, classified in class 514, subclass 12.
- DCCC. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and M-CSF, classified in class 514, subclass 12.
- 15 DCCCI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

- DCCCII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-1- $\beta$  and IL-1ra, classified in class 514, subclass 12.
- 5 DCCCIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-3, classified in class 514, subclass 12.
- DCCCIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-4, classified in class 514, subclass 12.
- 10 DCCCV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-5, classified in class 514, subclass 12.
- DCCCVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-6, classified in class 514, subclass 12.
- 15 DCCCVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-7, classified in class 514, subclass 12.

Art Unit: 1647

- DCCCVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-8, classified in class 514, subclass 12.
- 5 DCCCIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-10, classified in class 514, subclass 12.
- DCCCX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-11, classified in class 514, subclass 12.
- 10 DCCCXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-12, classified in class 514, subclass 12.
- DCCCXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IFN- $\alpha$ , classified in class 514, subclass 12.
- 15 DCCCXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IFN- $\beta$ , classified in class 514, subclass 12.



Art Unit: 1647

DCCCXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IFN- $\gamma$ , classified in class 514, subclass 12.

5 DCCCXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and oncostatin, classified in class 514, subclass 12.

DCCCXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and TNF- $\alpha$ , classified in class 514, subclass 12.

10 DCCCXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and TNF- $\beta$ , classified in class 514, subclass 12.

15 DCCCXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and GM-CSF, classified in class 514, subclass 12.

DCCCXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCCXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and M-CSF, classified in class 514, subclass 12.

5 DCCCXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and sTNFR, classified in class 514, subclass 12.

DCCCXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-2 and IL-1ra, classified in class 514, subclass 12.

10 DCCCXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-4, classified in class 514, subclass 12.

15 DCCCXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-5, classified in class 514, subclass 12.

DCCCXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-6, classified in class 514, subclass 12.

Art Unit: 1647

DCCCXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-7, classified in class 514, subclass 12.

5 DCCCXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-8, classified in class 514, subclass 12.

DCCCXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-10, classified in class 514, subclass 12.

10 DCCCXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-11, classified in class 514, subclass 12.

15 DCCCXXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-12, classified in class 514, subclass 12.

DCCCXXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IFN- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

DCCCXXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IFN- $\beta$ , classified in class 514, subclass 12.

5 DCCCXXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IFN- $\gamma$ , classified in class 514, subclass 12.

DCCCXXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and oncostatin, classified in class 514, subclass 12.

10 DCCCXXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and TNF- $\alpha$ , classified in class 514, subclass 12.

15 DCCCXXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and TNF- $\beta$ , classified in class 514, subclass 12.

DCCCXXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCCXXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and G-CSF, classified in class 514, subclass 12.

DCCCXXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and M-CSF, classified in class 514, subclass 12.

DCCCXL. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and sTNFR, classified in class 514, subclass 12.

DCCCXLI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-3 and IL-1ra, classified in class 514, subclass 12.

DCCCXLII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-5, classified in class 514, subclass 12.

DCCCXLIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-6, classified in class 514, subclass 12.

Art Unit: 1647

DCCCXLIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-7, classified in class 514, subclass 12.

5 DCCCXLV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-8, classified in class 514, subclass 12.

DCCCXLVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-10, classified in class 514, subclass 12.

10 DCCCXLVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-11, classified in class 514, subclass 12.

15 DCCCXLVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-12, classified in class 514, subclass 12.

DCCCXLIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IFN- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

- DCCCL. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IFN- $\beta$ , classified in class 514, subclass 12.
- 5 DCCCLI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IFN- $\gamma$ , classified in class 514, subclass 12.
- DCCCLII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and oncostatin, classified in class 514, subclass 12.
- 10 DCCCLIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and TNF- $\alpha$ , classified in class 514, subclass 12.
- DCCCLIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and 15 TNF- $\beta$ , classified in class 514, subclass 12.
- DCCCLV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCCLVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and G-CSF, classified in class 514, subclass 12.

5 DCCCLVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and M-CSF, classified in class 514, subclass 12.

DCCCLVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and sTNFR, classified in class 514, subclass 12.

10 DCCCLIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-4 and IL-1ra, classified in class 514, subclass 12.

15 DCCCLX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IL-6, classified in class 514, subclass 12.

DCCCLXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IL-7, classified in class 514, subclass 12.



Art Unit: 1647

DCCCLXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IL-8, classified in class 514, subclass 12.

5 DCCCLXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IL-10, classified in class 514, subclass 12.

DCCCLXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IL-11, classified in class 514, subclass 12.

10 DCCCLXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IL-12, classified in class 514, subclass 12.

15 DCCCLXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IFN- $\alpha$ , classified in class 514, subclass 12.

DCCCLXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IFN- $\beta$ , classified in class 514, subclass 12.

Art Unit: 1647

DCCCLXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IFN- $\gamma$ , classified in class 514, subclass 12.

5 DCCCLXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and oncostatin, classified in class 514, subclass 12.

DCCCLXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and TNF- $\alpha$ , classified in class 514, subclass 12.

10 DCCCLXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and TNF- $\beta$ , classified in class 514, subclass 12.

15 DCCCLXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and GM-CSF, classified in class 514, subclass 12.

DCCCLXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

DCCCLXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and M-CSF, classified in class 514, subclass 12.

DCCCLXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and sTNFR, classified in class 514, subclass 12.

DCCCLXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-5 and IL-1ra, classified in class 514, subclass 12.

DCCCLXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IL-7, classified in class 514, subclass 12.

DCCCLXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IL-8, classified in class 514, subclass 12.

DCCCLXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IL-10, classified in class 514, subclass 12.

Art Unit: 1647

DCCCLXXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IL-11, classified in class 514, subclass 12.

5 DCCCLXXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IL-12, classified in class 514, subclass 12.

DCCCLXXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IFN- $\alpha$ , classified in class 514, subclass 12.

10 DCCCLXXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IFN- $\beta$ , classified in class 514, subclass 12.

15 DCCCLXXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IFN- $\gamma$ , classified in class 514, subclass 12.

DCCCLXXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

- 5 DCCCLXXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and TNF- $\alpha$ , classified in class 514, subclass 12.
- 5 DCCCLXXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and TNF- $\beta$ , classified in class 514, subclass 12.
- 10 DCCCLXXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and GM-CSF, classified in class 514, subclass 12.
- 10 DCCCLXXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and G-CSF, classified in class 514, subclass 12.
- 15 DCCCXC. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and M-CSF, classified in class 514, subclass 12.
- DCCCXCI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

DCCCXCII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-6 and IL-1ra, classified in class 514, subclass 12.

5 DCCCXCIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IL-8, classified in class 514, subclass 12.

DCCCXCIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IL-10, classified in class 514, subclass 12.

10 DCCCXCV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IL-11, classified in class 514, subclass 12.

15 DCCCXCVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IL-12, classified in class 514, subclass 12.

DCCCXCVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IFN- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

DCCCXCVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IFN- $\beta$ , classified in class 514, subclass 12.

DCCCXCIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IFN- $\gamma$ , classified in class 514, subclass 12.

CM. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and oncostatin, classified in class 514, subclass 12.

CMI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and TNF- $\alpha$ , classified in class 514, subclass 12.

CMII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and TNF- $\beta$ , classified in class 514, subclass 12.

CMIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CMIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and G-CSF, classified in class 514, subclass 12.

CMV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and M-CSF, classified in class 514, subclass 12.

CMVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and sTNFR, classified in class 514, subclass 12.

CMVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-7 and IL-1ra, classified in class 514, subclass 12.

CMVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and IL-10, classified in class 514, subclass 12.

CMIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and IL-11, classified in class 514, subclass 12.



Art Unit: 1647

CMX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and IL-12, classified in class 514, subclass 12.

CMXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and IFN- $\alpha$ , classified in class 514, subclass 12.

CMXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and IFN- $\beta$ , classified in class 514, subclass 12.

CMXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and IFN- $\gamma$ , classified in class 514, subclass 12.

CMXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and oncostatin, classified in class 514, subclass 12.

CMXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and TNF- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

- CMXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and TNF- $\beta$ , classified in class 514, subclass 12.
- 5 CMXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and GM-CSF, classified in class 514, subclass 12.
- CMXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and G-CSF, classified in class 514, subclass 12.
- 10 CMXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and M-CSF, classified in class 514, subclass 12.
- CMXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and sTNFR, classified in class 514, subclass 12.
- 15 CMXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-8 and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

- CMXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and IL-11, classified in class 514, subclass 12.
- 5 CMXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and IL-12, classified in class 514, subclass 12.
- CMXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and IFN- $\alpha$ , classified in class 514, subclass 12.
- 10 CMXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and IFN- $\beta$ , classified in class 514, subclass 12.
- CMXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and IFN- $\gamma$ , classified in class 514, subclass 12.
- 15 CMXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

CMXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and TNF- $\alpha$ , classified in class 514, subclass 12.

CMXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and TNF- $\beta$ , classified in class 514, subclass 12.

CMXXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and GM-CSF, classified in class 514, subclass 12.

CMXXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and G-CSF, classified in class 514, subclass 12.

CMXXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and M-CSF, classified in class 514, subclass 12.

CMXXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

CMXXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-10 and IL-1ra, classified in class 514, subclass 12.

CMXXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and IL-12, classified in class 514, subclass 12.

CMXXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and IFN- $\alpha$ , classified in class 514, subclass 12.

CMXXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and IFN- $\beta$ , classified in class 514, subclass 12.

CMXXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and IFN- $\gamma$ , classified in class 514, subclass 12.

CMXXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

CMXL. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and TNF- $\alpha$ , classified in class 514, subclass 12.

CMXLI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and TNF- $\beta$ , classified in class 514, subclass 12.

CMXLII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and GM-CSF, classified in class 514, subclass 12.

CMXLIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and G-CSF, classified in class 514, subclass 12.

CMXLIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and M-CSF, classified in class 514, subclass 12.

CMXLV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

CMXLVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-11 and IL-1ra, classified in class 514, subclass 12.

CMXLVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and IFN- $\alpha$ , classified in class 514, subclass 12.

CMXLVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and IFN- $\beta$ , classified in class 514, subclass 12.

CMXLIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and IFN- $\gamma$ , classified in class 514, subclass 12.

CML. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and oncostatin, classified in class 514, subclass 12.

CMLI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and TNF- $\alpha$ , classified in class 514, subclass 12.

Art Unit: 1647

- 5 CMLII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and TNF- $\beta$ , classified in class 514, subclass 12.
- CMLIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and GM-CSF, classified in class 514, subclass 12.
- 10 CMLIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and G-CSF, classified in class 514, subclass 12.
- CMLV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and M-CSF, classified in class 514, subclass 12.
- 15 CMLVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and sTNFR, classified in class 514, subclass 12.
- CMLVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IL-12 and IL-1ra, classified in class 514, subclass 12.



Art Unit: 1647

CMLVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and IFN- $\beta$ , classified in class 514, subclass 12.

5 CMLIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and IFN- $\gamma$ , classified in class 514, subclass 12.

CMLX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and oncostatin, classified in class 514, subclass 12.

10 CMLXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and TNF- $\alpha$ , classified in class 514, subclass 12.

CMLXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.

15 CMLXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CMLXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and G-CSF, classified in class 514, subclass 12.

CMLXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and M-CSF, classified in class 514, subclass 12.

CMLXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and sTNFR, classified in class 514, subclass 12.

CMLXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\alpha$  and IL-1ra, classified in class 514, subclass 12.

CMLXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and IFN- $\gamma$ , classified in class 514, subclass 12.

CMLXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and oncostatin, classified in class 514, subclass 12.

Art Unit: 1647

CMLXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and TNF- $\alpha$ , classified in class 514, subclass 12.

5 CMLXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and TNF- $\beta$ , classified in class 514, subclass 12.

CMLXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and GM-CSF, classified in class 514, subclass 12.

10 CMLXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and G-CSF, classified in class 514, subclass 12.

CMLXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and M-CSF, classified in class 514, subclass 12.

15 CMLXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and sTNFR, classified in class 514, subclass 12.

Art Unit: 1647

CMLXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\beta$  and IL-1ra, classified in class 514, subclass 12.

CMLXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and oncostatin, classified in class 514, subclass 12.

CMLXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and TNF- $\alpha$ , classified in class 514, subclass 12.

CMLXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and TNF- $\beta$ , classified in class 514, subclass 12.

CMLXXX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and GM-CSF, classified in class 514, subclass 12.

CMLXXXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CMLXXXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and M-CSF, classified in class 514, subclass 12.

CMLXXXIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and sTNFR, classified in class 514, subclass 12.

CMLXXXIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising IFN- $\gamma$  and IL-1ra, classified in class 514, subclass 12.

CMLXXXV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising oncostatin and TNF- $\alpha$ , classified in class 514, subclass 12.

CMLXXXVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising oncostatin and TNF- $\beta$ , classified in class 514, subclass 12.

CMLXXXVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising oncostatin and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CMLXXXVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising oncostatin and G-CSF, classified in class 514, subclass 12.

CMLXXXIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising oncostatin and M-CSF, classified in class 514, subclass 12.

CMXC. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising oncostatin and sTNFR, classified in class 514, subclass 12.

CMXCI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising oncostatin and IL-1ra, classified in class 514, subclass 12.

CMXCII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\alpha$  and TNF- $\beta$ , classified in class 514, subclass 12.

CMXCIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\alpha$  and GM-CSF, classified in class 514, subclass 12.

Art Unit: 1647

CMXCIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\alpha$  and G-CSF, classified in class 514, subclass 12.

CMXCV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\alpha$  and M-CSF, classified in class 514, subclass 12.

CMXCVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\alpha$  and sTNFR, classified in class 514, subclass 12.

CMXCVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\alpha$  and IL-1ra, classified in class 514, subclass 12.

CMXCVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\beta$  and GM-CSF, classified in class 514, subclass 12.

CMXCIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\beta$  and G-CSF, classified in class 514, subclass 12.

Art Unit: 1647

M. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\beta$  and M-CSF, classified in class 514, subclass 12.

5 MI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\beta$  and sTNFR, classified in class 514, subclass 12.

MII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising TNF- $\beta$  and IL-1ra, classified in class 514, subclass 12.

10 MIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising GM-CSF and G-CSF, classified in class 514, subclass 12.

MIV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising GM-CSF and M-CSF, 15 classified in class 514, subclass 12.

MV. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising GM-CSF and sTNFR, classified in class 514, subclass 12.



Art Unit: 1647

MVI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising GM-CSF and IL-1ra, classified in class 514, subclass 12.

MVII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising G-CSF and M-CSF, classified in class 514, subclass 12.

MVIII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising G-CSF and sTNFR, classified in class 514, subclass 12.

MIX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising G-CSF and IL-1ra, classified in class 514, subclass 12.

MX. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising M-CSF and sTNFR, classified in class 514, subclass 12.

MXI. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising M-CSF and IL-1ra, classified in class 514, subclass 12.

Art Unit: 1647

MXII. Claim(s) 24, to the extent that it is drawn to a method of treating inflammation comprising administering a composition comprising sTNFR and IL-1ra, classified in class 514, subclass 12.

2. The inventions are distinct, each from the other because of the following reasons:

5 a. The following pairwise combinations of products are independent and distinct, wherein neither member of a pair is required for the production or use of the other, and wherein each of the pair can be manufactured independently of the other and used for independent and distinct purposes: I and each of II-CCLIII;

II and each of III-CCLIII;

10 III and each of IV-CCLIII;

IV and each of V-CCLIII;

V and each of VI-CCLIII;

VI and each of VII-CCLIII;

VII and each of VIII-CCLIII;

15 VIII and each of IX-CCLIII;

IX and each of X-CCLIII;

X and each of XI-CCLIII;

XI and each of XII-CCLIII;

XII and each of XIII-CCLIII;

Art Unit: 1647

XIII and each of XIV-CCLIII;

XIV and each of XV-CCLIII;

XV and each of XVI-CCLIII;

XVI and each of XVII-CCLIII;

5 XVII and each of XVIII-CCLIII;

XVIII and each of XIX-CCLIII;

XIX and each of XX-CCLIII;

XX and each of XXI-CCLIII;

XXI and each of XXII-CCLIII;

10 XXII and each of XXIII-CCLIII;

XXIII and each of XXIV-CCLIII;

XXIV and each of XXV-CCLIII;

XXV and each of XXVI-CCLIII;

XXVI and each of XXVII-CCLIII;

15 XXVII and each of XXVIII-CCLIII;

XXVIII and each of XXIX-CCLIII;

XXIX and each of XXX-CCLIII;

XXX and each of XXXI-CCLIII;

XXXI and each of XXXII-CCLIII;

Art Unit: 1647

XXXII and each of XXXIII-CCLIII;

XXXIII and each of XXXIV-CCLIII;

XXXIV and each of XXXV-CCLIII;

XXXV and each of XXXVI-CCLIII;

5 XXXVI and each of XXXVII-CCLIII;

XXXVII and each of XXXVIII-CCLIII;

XXXVIII and each of XXXIX-CCLIII;

XXXIX and each of XL-CCLIII;

XL and each of XLI-CCLIII;

10 XLI and each of XLII-CCLIII;

XLII and each of XLIII-CCLIII;

XLIII and each of XLIV-CCLIII;

XLIV and each of XLV-CCLIII;

XLV and each of XLVI-CCLIII;

15 XLVI and each of XLVII-CCLIII;

XLVII and each of XLVIII-CCLIII;

XLVIII and each of XLIX-CCLIII;

XLIX and each of L-CCLIII;

L and each of LI-CCLIII;

Art Unit: 1647

LI and each of LII-CCLIII;

LII and each of LIII-CCLIII;

LIII and each of LIV-CCLIII;

LIV and each of LV-CCLIII;

5 LV and each of LVI-CCLIII;

LVI and each of LVII-CCLIII;

LVII and each of LVIII-CCLIII;

LVIII and each of LIX-CCLIII;

LIX and each of LX-CCLIII;

10 LX and each of LXI-CCLIII;

LXI and each of LXII-CCLIII;

LXII and each of LXIII-CCLIII;

LXIII and each of LXIV-CCLIII;

LXIV and each of LXV-CCLIII;

15 LXV and each of LXVI-CCLIII;

LXVI and each of LXVII-CCLIII;

LXVII and each of LXVIII-CCLIII;

LXVIII and each of LXIX-CCLIII;

LXIX and each of LXX-CCLIII;

Art Unit: 1647

LXX and each of LXXI-CCLIII;

LXXI and each of LXXII-CCLIII;

LXXII and each of LXXIII-CCLIII;

LXXIII and each of LXXIV-CCLIII;

5 LXXIV and each of LXXV-CCLIII;

LXXV and each of LXXVI-CCLIII;

LXXVI and each of LXXVII-CCLIII;

LXXVII and each of LXXVIII-CCLIII;

LXXVIII and each of LXXIX-CCLIII;

10 LXXIX and each of LXXX-CCLIII;

LXXX and each of LXXXI-CCLIII;

LXXXI and each of LXXXII-CCLIII;

LXXXII and each of LXXXIII-CCLIII;

LXXXIII and each of LXXXIV-CCLIII;

15 LXXXIV and each of LXXXV-CCLIII;

LXXXV and each of LXXXVI-CCLIII;

LXXXVI and each of LXXXVII-CCLIII;

LXXXVII and each of LXXXVIII-CCLIII;

LXXXVIII and each of LXXXIX-CCLIII;

Art Unit: 1647

LXXXIX and each of XC-CCLIII;

XC and each of XCI-CCLIII;

XCI and each of XCII-CCLIII;

XCII and each of XCIII-CCLIII;

5 XCIII and each of XCIV-CCLIII;

XCIV and each of XCV-CCLIII;

XCV and each of XCVI-CCLIII;

XCVI and each of XCVII-CCLIII;

XCVII and each of XCVIII-CCLIII;

10 XCVIII and each of XCIX-CCLIII;

XCIX and each of C-CCLIII;

C and each of CI-CCLIII;

CI and each of CII-CCLIII;

CII and each of CIII-CCLIII;

15 CIII and each of CIV-CCLIII;

CIV and each of CV-CCLIII;

CV and each of CVI-CCLIII;

CVI and each of CVII-CCLIII;

CVII and each of CVIII-CCLIII;

Art Unit: 1647

CVIII and each of CIX-CCLIII;

CIX and each of CX-CCLIII;

CX and each of CXI-CCLIII;

CXI and each of CXII-CCLIII;

5 CXII and each of CXIII-CCLIII;

CXIII and each of CXIV-CCLIII;

CXIV and each of CXV-CCLIII;

CXV and each of CXVI-CCLIII;

CXVI and each of CXVII-CCLIII;

10 CXVII and each of CXVIII-CCLIII;

CXVIII and each of CXIX-CCLIII;

CXIX and each of CXX-CCLIII;

CXX and each of CXXI-CCLIII;

CXXI and each of CXXII-CCLIII;

15 CXXII and each of CXXIII-CCLIII;

CXXIII and each of CXXIV-CCLIII;

CXXIV and each of CXXV-CCLIII;

CXXV and each of CXXVI-CCLIII;

CXXVI and each of CXXVII-CCLIII;



Art Unit: 1647

CXXVII and each of CXXVIII-CCLIII;

CXXVIII and each of CXXIX-CCLIII;

CXXIX and each of CXXX-CCLIII;

CXXX and each of CXXXI-CCLIII;

5 CXXXI and each of CXXXII-CCLIII;

CXXXII and each of CXXXIII-CCLIII;

CXXXIII and each of CXXXIV-CCLIII;

CXXXIV and each of CXXXV-CCLIII;

CXXXV and each of CXXXVI-CCLIII;

10 CXXXVI and each of CXXXVII-CCLIII;

CXXXVII and each of CXXXVIII-CCLIII;

CXXXVIII and each of CXXXIX-CCLIII;

CXXXIX and each of CXL-CCLIII;

CXL and each of CXLI-CCLIII;

15 CXLI and each of CXLII-CCLIII;

CXLII and each of CXLIII-CCLIII;

CXLIII and each of CXLIV-CCLIII;

CXLIV and each of CXLV-CCLIII;

CXLV and each of CXLVI-CCLIII;

Art Unit: 1647

CXLVI and each of CXLVII-CCLIII;

CXLVII and each of CXLVIII-CCLIII;

CXLVIII and each of CXLIX-CCLIII;

CXLIX and each of CL-CCLIII;

5 CL and each of CLI-CCLIII;

CLI and each of CLII-CCLIII;

CLII and each of CLIII-CCLIII;

CLIII and each of CLIV-CCLIII;

CLIV and each of CLV-CCLIII;

10 CLV and each of CLVI-CCLIII;

CLVI and each of CLVII-CCLIII;

CLVII and each of CLVIII-CCLIII;

CLVIII and each of CLIX-CCLIII;

CLIX and each of CLX-CCLIII;

15 CLX and each of CLXI-CCLIII;

CLXI and each of CLXII-CCLIII;

CLXII and each of CLXIII-CCLIII;

CLXIII and each of CLXIV-CCLIII;

CLXIV and each of CLXV-CCLIII;

Art Unit: 1647

CLXV and each of CLXVI-CCLIII;

CLXVI and each of CLXVII-CCLIII;

CLXVII and each of CLXVIII-CCLIII;

CLXVIII and each of CLXIX-CCLIII;

5 CLXIX and each of CLXX-CCLIII;

CLXX and each of CLXXI-CCLIII;

CLXXI and each of CLXXII-CCLIII;

CLXXII and each of CLXXIII-CCLIII;

CLXXIII and each of CLXXIV-CCLIII;

10 CLXXIV and each of CLXXV-CCLIII;

CLXXV and each of CLXXVI-CCLIII;

CLXXVI and each of CLXXVII-CCLIII;

CLXXVII and each of CLXXVIII-CCLIII;

CLXXVIII and each of CLXXIX-CCLIII;

15 CLXXIX and each of CLXXX-CCLIII;

CLXXX and each of CLXXXI-CCLIII;

CLXXXI and each of CLXXXII-CCLIII;

CLXXXII and each of CLXXXIII-CCLIII;

CLXXXIII and each of CLXXXIV-CCLIII;

Art Unit: 1647

CLXXXIV and each of CLXXXV-CCLIII;  
CLXXXV and each of CLXXXVI-CCLIII;  
CLXXXVI and each of CLXXXVII-CCLIII;  
CLXXXVII and each of CLXXXVIII-CCLIII;  
5 CLXXXVIII and each of CLXXXIX-CCLIII;  
CLXXXIX and each of CXC-CCLIII;  
CXC and each of CXCI-CCLIII;  
CXCI and each of CXCII-CCLIII;  
CXCII and each of CXCI-CCLIII;  
10 CXCI and each of CXCIV-CCLIII;  
CXCIV and each of CXCV-CCLIII;  
CXCV and each of CXCVI-CCLIII;  
CXCVI and each of CXCVII-CCLIII;  
CXCVII and each of CXCVIII-CCLIII;  
15 CXCVIII and each of CXCIX-CCLIII;  
CXCIX and each of CC-CCLIII;  
CC and each of CCI-CCLIII;  
CCI and each of CCII-CCLIII;  
CCII and each of CCIII-CCLIII;

Art Unit: 1647

CCIII and each of CCIV-CCLIII;

CCIV and each of CCV-CCLIII;

CCV and each of CCVI-CCLIII;

CCVI and each of CCVII-CCLIII;

5 CCVII and each of CCVIII-CCLIII;

CCVIII and each of CCIX-CCLIII;

CCIX and each of CCX-CCLIII;

CCX and each of CCXI-CCLIII;

CCXI and each of CCXII-CCLIII;

10 CCXII and each of CCXIII-CCLIII;

CCXIII and each of CCXIV-CCLIII;

CCXIV and each of CCXV-CCLIII;

CCXV and each of CCXVI-CCLIII;

CCXVI and each of CCXVII-CCLIII;

15 CCXVII and each of CCXVIII-CCLIII;

CCXVIII and each of CCXIX-CCLIII;

CCXIX and each of CCXX-CCLIII;

CCXX and each of CCXXI-CCLIII;

CCXXI and each of CCXXII-CCLIII;

Art Unit: 1647

CCXXII and each of CCXXIII-CCLIII;

CCXXIII and each of CCXXIV-CCLIII;

CCXXIV and each of CCXXV-CCLIII;

CCXXV and each of CCXXVI-CCLIII;

5 CCXXVI and each of CCXXVII-CCLIII;

CCXXVII and each of CCXXVIII-CCLIII;

CCXXVIII and each of CCXXIX-CCLIII;

CCXXIX and each of CCXXX-CCLIII;

CCXXX and each of CCXXXI-CCLIII;

10 CCXXXI and each of CCXXXII-CCLIII;

CCXXXII and each of CCXXXIII-CCLIII;

CCXXXIII and each of CCXXXIV-CCLIII;

CCXXXIV and each of CCXXXV-CCLIII;

CCXXXV and each of CCXXXVI-CCLIII;

15 CCXXXVI and each of CCXXXVII-CCLIII;

CCXXXVII and each of CCXXXVIII-CCLIII;

CCXXXVIII and each of CCXXXIX-CCLIII;

CCXXXIX and each of CCXL-CCLIII;

CCXL and each of CCXLI-CCLIII;

Art Unit: 1647

CCXLI and each of CCXLII-CCLIII;

CCXLII and each of CCXLIII-CCLIII;

CCXLIII and each of CCXLIV-CCLIII;

CCXLIV and each of CCXLV-CCLIII;

5 CCXLV and each of CCXLVI-CCLIII;

CCXLVI and each of CCXLVII-CCLIII;

CCXLVII and each of CCXLVIII-CCLIII;

CCXLVIII and each of CCXLIX-CCLIII;

CCXLIX and each of CCL-CCLIII;

10 CCL and each of CCLI-CCLIII;

CCLI and each of CCLII-CCLIII;

CCLII and each of CCLIII-CCLIII;

b. Invention CCLIV and each of I-CCLIII are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)).

15 In the instant case each of I-CCLIII could be made by mixing the two cytokines together.

c. Each of Inventions I-CCLIII and each of CCLV-DVII, respectively, are related as product and process of use. The inventions can be shown to be distinct if either or both of the

Art Unit: 1647

following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case Each of Inventions I-CCLIII could be used in DVIII-MXIII or in vitro as a cell culture additive.

5           d.       Each of Inventions I-CCLIII and each of DVIII-DCCLX, respectively, are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case Each of  
10       Inventions I-CCLIII could be used in CCLV-DVII, DCCLXI-MXIII or in vitro as a cell culture additive.

          e.       Each of Inventions I-CCLIII and each of DCCLXI-MXIII, respectively, are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with  
15       another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case Each of Inventions I-CCLIII could be used in DVIII-MXIII or in vitro as a cell culture additive.

          f.       The following pairwise combinations of methods are independent and distinct, wherein each member of a pair performs different functions, using different starting materials



Art Unit: 1647

and/or process steps and/or with different outcomes: CCLIV and each of CCLV-MXIII; each of CCLV-MXIII.

3. This application contains claims directed to the following patentably distinct species of the claimed invention: each of the priming agents in claim 13.

5 Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims <sup>11</sup>~~12~~-21 are generic.

12/16/11  
Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

10 Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

15 Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Art Unit: 1647

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

4. This application contains claims directed to the following patentably distinct species of the claimed invention: each of the cell lines in claim 16-21.

5 Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 12-21 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

10 Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

15 Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Art Unit: 1647

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).


ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (703) 305-4050. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH FRIDAY FROM 7:30 A.M. TO 4:00 P.M.

IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (703) 308-4623.

OFFICIAL PAPERS FILED BY FAX SHOULD BE DIRECTED TO (703) 308-4242.

FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (703) 308-0294.

ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.

  
DAVID ROMEO  
PRIMARY EXAMINER  
ART UNIT 1647

DECEMBER 16, 2001